32 research outputs found
Informant Personality Is Associated With Ratings of Memory Problems in Older Adults
Memory complaints are a key diagnostic criterion for dementia and Mild Cognitive Impairment. Rating scales can be used to capture information about individualsâ memory problems from informants such as family members. However, problems with scale reliability suggest that individual differences influence the ratings informants provide. This project tested whether informantsâ neuroticism was associated with their ratings of an older adultâs memory. In an online study, 293 volunteers completed a Five Factor personality questionnaire and used two memory questionnaires to provide ratings of memory problems in an older individual they knew well. Rater neuroticism correlated positively with estimates of memory problems: more neurotic informants provided higher estimates of memory difficulties in the person they were rating. A second study replicated this finding with 786 volunteers and another widely used memory measure, the AD8. In both studies, exploratory analyses suggested the effect size was large enough to impact on clinical practice
Police performance measurement: an annotated bibliography
This study provides information to assist those involved in performance measurement in police organisations. The strategies used to identify the literature are described. Thematic sections cover; general overviews; methodological issues; performance management in other industries; national, international and cross-national studies; frameworks (e.g. Compstat; the Balanced Scorecard); criticisms (particularly unintended consequences); crime-specific measures; practitioner guides; performance evaluation of individual staff; police department plans and evaluations; annotated bibliographies in related areas, and; other literature. Our discussion offers two conclusions: the measures best aligned with performance are typically more expensive, while most operational data should only provide contextual information; the philosophy of open governance should be pursued to promote transparency, accountability and communication to improve police performance
Large-Scale Structure in the Durham/UKST Galaxy Redshift Survey
We report on the progress of the compilation and analysis of the Durham/UKST galaxy redshift survey. This survey will probe a large contiguous volume of space within a 1500 sq. deg. area of sky around the SGP. It will contain redshifts of âź 4000 galaxies of bj, l0hâ1 Mpc
Recommended from our members
Erratum: Baryon acoustic oscillations in the Sloan Digital Sky Survey Data Release 7 galaxy sample
Stavudine extended release (once-daily, Bristol-Myers Squibb) for the treatment of HIV/AIDS
Penetration, distribution and kinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human skin in vitro
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
The treatment of patients with ovarian cancer is rapidly changing following the success of poly [ADP-ribose] polymerase (PARP) inhibitors in clinical trials. Olaparib is the first PARP inhibitor to be approved by the EMA and FDA for BRCA-mutated ovarian cancer. Germ line BRCA mutation status is now established as a predictive biomarker of potential benefit from treatment with a PARP inhibitor; therefore, knowledge of the BRCA status of an individual patient with ovarian cancer is essential, in order to guide treatment decisions. BRCA testing was previously offered only to women with a family or personal history of breast and/or ovarian cancer; however, almost 20% of women with high-grade serous ovarian cancer are now recognized to harbour a germ line BRCA mutation, and of these, >40% might not have a family history of cancer and would not have received BRCA testing. A strategy to enable more widespread implementation of BRCA testing in routine care is, therefore, necessary. In this Review, we summarize data from key clinical trials of PARP inhibitors and discuss how to integrate these agents into the current treatment landscape of ovarian cancer. The validity of germ line BRCA testing and other promising biomarkers of homologous-recombination deficiency will also be discussed